(+)-(S)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo<4,5,1-jk><1,4>benzodiazepine-2(1H)-thione | 126347-69-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (+)-(S)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo<4,5,1-jk><1,4>benzodiazepine-2(1H)-thione
• 英文别名: (+)-S-4,5,6,7-tetrahydroimidazo-9-chloro-5-methyl-6-(3-methylbut-2-enyl)imidazo<4.5.1-jk><1,4>benzodiazepin-2(1H)-thione；(+)-(5S)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo<4,5,1-jk><1,4>benzodiazepine-2(1H)-thione；(+)-(S)-9-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo<4,5,1-jk><1,4>benzodiazepine-2(1H)-thione；TIBO R82913；R-82913；R82913；4-Chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2H-2,7,9A-triaza-benzo[CD]azulene-1-thione；(11S)-6-chloro-11-methyl-10-(3-methylbut-2-enyl)-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-triene-2-thione
• CAS: 126347-69-1
• 化学式: C₁₆H₂₀ClN₃S
• 分子量: 321.874
• InChiKey: RCSLUNOLLUVOOG-NSHDSACASA-N

物化性质

• 沸点：
  429.7±55.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  50.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,5-二氯-3-硝基苯甲酸 在 palladium on activated charcoal 草酰氯 、 dimethyl sulfide borane 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 反应 212.0h， 生成 (+)-(S)-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo<4,5,1-jk><1,4>benzodiazepine-2(1H)-thione
  参考文献：
  名称：

  Regioselectivity in intramolecular nucleophilic aromatic substitution. Synthesis of the potent anti HIV-I 8-halo TIBO analogs

  摘要：

  Regioselective intramolecular nucleophilic substitution of 2,6-dihalo-3-nitrobenzyl diamines 2b and 2c gave benzodiazepines 3. These intermediates are useful in the preparation of the 8-halo TIBO derivatives 1, inhibitors of HIV-I replication in cell culture.

  DOI：

  10.1021/jo00027a019

文献信息

• Phospho-indoles as HIV inhibitors
  申请人：Storer Richard

  公开号：US20060074054A1

  公开（公告）日：2006-04-06

  3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

  描述了用于治疗逆转录病毒感染，特别是HIV的3-磷酸吲哚化合物。还包括仅含有3-磷酸吲哚衍生物或与一个或多个其他抗逆转录病毒药物组合的组合物，它们的制备过程，以及制造包含这些化合物的药物的方法。
• Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2
  作者：Michael J. Kukla、Henry J. Breslin、Craig J. Diamond、Philip P. Grous、Chih Y. Ho、Milton Miranda、James D. Rodgers、Ronald G. Sherrill、Erik De Clercq、Rudi Pauwels、Koen Andries、Luc J. Moens、Marcel A. C. Janssen、Paul A. J. Janssen

  DOI：10.1021/jm00115a007

  日期：1991.11.1

  substituent (R) attached at the N-6 position of 9. This study describes the syntheses and anti-HIV-1 testing of analogues with variations of the five-membered urea ring of the 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) structures. Although many different rings were synthesized to replace the cyclic urea of TIBO, most were found to be inactive in inhibiting the replication

  在该系列的第一篇论文中，揭示了一种具有抗HIV-1活性的新结构，并合成了类似物以探讨9位N-6位上连接的取代基（R）的变化与构效关系。描述了具有4,5,6,7-四氢-5-甲基咪唑[4,5,1-jk] [1,4]的五元脲环变异的类似物的合成和抗HIV-1测试苯并二氮杂-2-2（1H）-一（TIBO）结构。尽管合成了许多不同的环来取代TIBO的环状脲，但发现大多数环在抑制MT-1细胞中HIV-1病毒的复制方面没有活性。例外是用硫或硒代替尿素氧，得到相应的硫脲或硒脲。发现它们比氧气对应物更具活性。合成并测试了一小部分类似物，可以直接比较尿素和硫脲衍生物。毫无例外，后者总是比前者更加活跃。发现该系列（8d）中活性最高的化合物抑制HIV-1病毒，其IC50为0.012 microM，与AZT相当。
• [EN] USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION<br/>[FR] UTILISATION DE COMPOSES BHAP EN COMBINAISON AVEC D'AUTRES INHIBITEURS DE LA TRANSCRIPTASE INVERSE NON-NUCLEOSIDIQUES DANS LE TRAITEMENT DES INFECTIONS A VIH
  申请人：THE UPJOHN COMPANY

  公开号：WO1994009781A1

  公开（公告）日：1994-05-11

  (EN) The present invention are methods of treating a HIV positive human which comprises (1) administering to the HIV positive individual a sensitizingly effective amount of a SENSITIZING HIV-1 INHIBITOR until increased sensitivity to a NON-NUCLEOSIDE HIV TREATMENT DRUG develops, (2) administering to the HIV positive individual an effective amount of a NON-NUCLEOSIDE HIV TREATMENT DRUG. An alternative method is a method of treating a HIV positive human which comprises administering to the HIV positive individual a sensitizingly effective amount of one or more SENSITIZING HIV-1 INHIBITOR concurrently with an effective amount of a NON-NUCLEOSIDE HIV TREATMENT DRUG.(FR) La présente invention se rapporte à des procédés de traitement d'un patient séropositif consistant à (1) administrer au patient séropositif une dose efficace sensibilisante d'un inhibiteur du VIH-1 sensibilisant jusqu'à ce qu'une sensibilité accrue à un médicament non-nucléosidique traitant le VIH se développe, (2) administrer au patient séropositif une dose efficace d'un médicament non-nucléosidique traitant le VIH. Une autre variante du procédé de traitement d'un patient séropositif consiste à administrer au patient séropositif une dose efficace sensibilisante d'un ou de plusieurs inhibiteurs du VIH sensibilisants, en même temps qu'une dose efficace d'un médicament non-nucléosidique traitant le VIH.

  本发明涉及治疗艾滋病毒（HIV）阳性人群的方法，包括：（1）向HIV阳性个体施用足够的敏感性HIV-1抑制剂，直到对非核苷类HIV治疗药物产生增加敏感性，（2）向HIV阳性个体施用足够的非核苷类HIV治疗药物。另一种方法是同时向HIV阳性个体施用足够的一种或多种敏感性HIV-1抑制剂和足够的非核苷类HIV治疗药物。
• Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
  申请人：Mitsubishi Chemical Corporation

  公开号：EP0631783A1

  公开（公告）日：1995-01-04

  Antiviral agents which comprises as active ingredients one or more 2',3'-dideoxyribonucleosides or phosphoric esters thereof and 6-benzyl-1-ethoxymethyl-5-substituted uracil derivative of the formula (I): wherein X is oxygen or sulfur atom; R¹ is ethyl or isopropyl; R² and R³ are independently hydrogen atom, C₁ - C₃ alkyl or halogen atom, which compounds can inhibit HIV reverse transcriptase through different mechanisms and are synergistic in combination.

  抗病毒药剂包括以下活性成分：一个或多个2'，3'-二脱氧核苷或其磷酸酯和式（I）的6-苄基-1-乙氧甲基-5-取代尿嘧啶衍生物，其中X是氧或硫原子；R¹是乙基或异丙基；R²和R³独立地是氢原子，C₁-C₃烷基或卤素原子，这些化合物可以通过不同机制抑制HIV反转录酶，并在组合中具有协同作用。
• Calanolide and related antiviral compounds, compositions, and uses thereof
  申请人：——

  公开号：US20020086898A1

  公开（公告）日：2002-07-04

  The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

  本发明提供了新型的抗病毒化合物，称为卡拉诺利德（calanolides）、相关化合物及其衍生物，可从山竹子属（Calophyllum）植物中分离或从该属植物的化合物中衍生出来，符合本发明方法。这些化合物及其衍生物可单独使用或与其他抗病毒药物组合在一起，形成组成物，如制药组成物，以抑制病毒的生长或复制，如逆转录病毒，特别是人类免疫缺陷病毒，具体是HIV-1或HIV-2。